VALDOXAN (Agomelatine), Novel MELATONERGIC antidepressant Options

[Kazan]

As information for all I add that Servier Laboratories (of Stablon) is starting to market a new antidepressant named Valdoxan (Agomelatine).

As I understand it just coming out in Britain. This is a very novel antidepressant. It is a Melatonergic in action, it increases (agonist) the activity of the receptors for Melatonin at M1 and M2 and decreases (antagonist) the activity of the receptor for Serotonin 5HT2c.

Novartis obtained the license to market it in the U.S. and has submitted it to the FDA where, I believe, it lingers until their patent on their own antidepressant (SSRI) expires.

Since it is from Servier, the innovator with Survector and Stablon there is hope that it may also be effective, but that remain to be seen—if it is effective it may “run of the mill” and NOT have neuroenhancing or activating properties.

I've been researching this antidepressant online for years and feel convinced that it must be totally different in its effect, but an actual trial is the only final determiner. The purported lack of side-effects or tolerability is paramount in its use.

I haven’t being able to locate a source at all yet, so would appreciate knowing if someone has